Drug - maker Catalent has agreed a $ 1.2bn deal to acquire UK - based Paragon Bioservices , according to a report in The Wall Street Journal . The Baltimore, Maryland-based company is expected to record more than $200 million in revenue this year, the Journal said. The deal is expected to enable it to pursue the development of specialised gene therapy products . Neither company has confirmed the report .
Drug - maker Catalent has agreed a $ 1.2bn deal to acquire UK - based Paragon Bioservices , according to a report in The Wall Street Journal . The deal is expected to enable it to pursue the development of specialised gene therapy products . Neither company has confirmed the report .